Complaint Counsel's Post Trial Brief - Federal Trade Commission
Complaint Counsel's Post Trial Brief - Federal Trade Commission
Complaint Counsel's Post Trial Brief - Federal Trade Commission
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
352. LaMont acknowledged that there have been no clinical studies perormed on the DCO<br />
Products. (R22 (LaMont, Dep. at 48); LaMont, Tr. 579).<br />
353. The DCO products "are not silver bullets." (R22 (LaMont, Dep. at 127)).<br />
354. LaMont does not know the Feijos. (R22 (LaMont, Dep. at 49)).<br />
their oncologist<br />
and utilze protocols that are proven to be most effective for their cancer and that they<br />
355. LaMont this that it is "best that people follow the recommendations of<br />
should be well-informed of the potential value of the aray of other therapies." (R22<br />
(LaMont, Dep. at 49)).<br />
I'm workig with a patient, I'm going to insist that<br />
they work with their oncologist and follow their advice and I'm going to comanage their<br />
care." (R22 (LaMont, Dep. at 51-52)).<br />
356. LaMont testified that "as a doctor, if<br />
plant<br />
foods and medicines should not influence patients with cancer and other serous diseases<br />
to abandon using the most effective methods that moder medicine has to offer." (R22<br />
(LaMont, Dep. at 52)).<br />
357. LaMont believes that "(t)he awareness of the powerl chemoprotective effects of<br />
358. LaMont would not be comfortable with the Feijos sayig that the DCO products are<br />
going to cure cancer. (R22 (LaMont, Dep. at 53)).<br />
359. LaMont can see why the <strong>Federal</strong> <strong>Trade</strong> <strong>Commission</strong> would have concers about the<br />
statement that DCO's products are cancer solutions. (R22 (LaMont, Dep. at 127)).<br />
360. LaMont would not have wrtten the text that way to include "cancer solutions" next to the<br />
DCO products. (R22 (LaMont, Dep. at 128)).<br />
361. LaMont does not "believe that on their own across the board these (DCO) products are<br />
going to effectively treat cancer." (R22 (LaMont, Dep. at 53)).<br />
362. LaMont did not listen to the Feijo's radio show nor did she have the interest in listenig<br />
to their show. (R22 (LaMont, Dep. at 77)).<br />
that she would defend the DCO products because she has limted<br />
363. LaMont did not say<br />
knowledge of their products. (R22 (LaMont, Dep. at 78)).<br />
364. LaMont has never used the DCO products. (R22 (LaMont, Dep. at 78); LaMont, Tr. 578<br />
79).<br />
365. LaMont has not studied the DCO products specifically. (R22 (LaMont, Dep. at 87-88);<br />
LaMont, Tr. 579).<br />
366. LaMont acknowledges that traditional use evidence does not replace human clinical<br />
trals. (R22 (LaMont, Dep. at 89); LaMont, Tr. 584).<br />
367. LaMont acknowledges that it is not a common occurence in the industr to make cancer<br />
cure or cancer treatment claims. (R22 (LaMont, Dep. at 144-45)).<br />
32